中国抗体制药有限公司（股票代码：03681，股票名称：中国抗体-B）于报告期内先后进行二零二五年五月股份认购及二零二五年七月股份认购，筹得的款项净额均按此前于二零二五年五月十三日、二零二五年八月十五日、二零二五年七月二十一日及二零二六年三月二十三日的相关公告中披露的既定用途使用。
报告期内，公司基于此前获授的股份奖励计划，合计有1,220,000份奖励实现归属。其中，85,000份在报告期内被行使，每股行使价为1.12港元，平均收市价约1.69港元，公司因此获得的款项总额约为95,200港元。投资者可参阅二零二五年年报第58至61页以及前述日期的公告了解更多详情。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.